- Divi’s Labs reported a net income of 6.62 billion rupees for the fourth quarter, a 23% increase year-over-year, surpassing estimates of 6.15 billion rupees.
- Revenue for the quarter was 25.85 billion rupees, a 12% increase year-over-year, beating the estimated 25.55 billion rupees.
- Total costs increased by 8.3% year-over-year to 18.07 billion rupees.
- Raw material costs were reported at 9.31 billion rupees, marking a 3.7% increase from the previous year.
- Employee benefits expenses rose significantly by 18% year-over-year to 3.50 billion rupees, higher than the estimated 3.25 billion rupees.
- Other income for the quarter was 860 million rupees, up 8.9% compared to last year.
- A dividend of 30 rupees per share was declared.
- Venkatesa Perumallu Pasumarthy has been appointed as the Chief Financial Officer, effective from August 1.
- The commercial operations have commenced at the Unit III greenfield project located at Ontimamidi Village, near Kakinada, Andhra Pradesh.
- The company capitalized assets worth 11.18 billion rupees during the financial year, including 7.55 billion rupees for Unit III at Kakinada.
A look at Divi’s Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Divi’s Laboratories Ltd., a pharmaceutical company specializing in generic drugs and intermediates, has been rated using Smartkarma Smart Scores. With a solid Resilience score of 5 and Momentum score of 5, the company is positioned for long-term stability and growth. The Growth and Dividend scores both at 3 indicate moderate performance in these areas. However, the Value score of 2 suggests that the company may be slightly overvalued compared to its industry peers.
Looking ahead, Divi’s Laboratories‘ overall outlook appears positive with strong resilience and momentum driving its future prospects. Investors may see potential for growth and stability in the company’s operations. With a focus on pharmaceutical manufacturing and contract research, Divi’s Laboratories could be well-positioned to capitalize on opportunities in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
